The first stop for professional medicines advice

Musculo-skeletal disorders, Medicines planning

7 results

Applied filters

Preparing to use golimumab biosimilar

21 May 2025Golimumab biosimilars are expected soon. We offer general information and implementation advice.

Good governance when implementing ustekinumab biosimilar

2 August 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.

The licence and supporting evidence for ustekinumab biosimilars

2 August 2024Ustekinumab biosimilars (Pyzchiva, Steqeyma, Uzpruvo, Wezenla) are licensed. Learn about indications, formulations, supporting evidence and differences.

Preparing to use ustekinumab biosimilar

16 July 2024Introducing biosimilar ustekinumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.

Good governance when implementing tocilizumab biosimilar

5 March 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.

The licence and supporting evidence for tocilizumab biosimilar

5 March 2024One licensed tocilizumab biosimilar is available: Tyenne. Learn about the licensed indications, supporting evidence and key differences.

Preparing to use tocilizumab biosimilar

5 March 2024Introducing biosimilar tocilizumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.